• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Interactions between SARS coronavirus 2 papain-like protease and immune system: A potential drug target for the treatment of COVID-19.严重急性呼吸综合征冠状病毒 2 型木瓜蛋白酶样蛋白酶与免疫系统的相互作用:COVID-19 治疗的潜在药物靶点。
Scand J Immunol. 2021 Oct;94(4):e13044. doi: 10.1111/sji.13044. Epub 2021 Aug 10.
2
Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity.木瓜蛋白酶样蛋白酶调节新型冠状病毒2的病毒传播和固有免疫。
Nature. 2020 Nov;587(7835):657-662. doi: 10.1038/s41586-020-2601-5. Epub 2020 Jul 29.
3
Unraveling antiviral efficacy of multifunctional immunomodulatory triterpenoids against SARS-COV-2 targeting main protease and papain-like protease.解析多功能免疫调节三萜类化合物针对 SARS-COV-2 主蛋白酶和木瓜蛋白酶样蛋白酶的抗病毒功效。
IUBMB Life. 2024 May;76(5):228-241. doi: 10.1002/iub.2793. Epub 2023 Dec 7.
4
Deubiquitinating activity of SARS-CoV-2 papain-like protease does not influence virus replication or innate immune responses in vivo.SARS-CoV-2 木瓜蛋白酶样蛋白酶的去泛素化活性不会影响病毒在体内的复制或先天免疫反应。
PLoS Pathog. 2024 Mar 25;20(3):e1012100. doi: 10.1371/journal.ppat.1012100. eCollection 2024 Mar.
5
Ciclesonide Inhibits SARS-CoV-2 Papain-Like Protease in Vitro.地塞米松抑制 SARS-CoV-2 木瓜样蛋白酶的体外研究。
Biol Pharm Bull. 2024;47(5):965-966. doi: 10.1248/bpb.b24-00038.
6
MERS-CoV papain-like protease has deISGylating and deubiquitinating activities.MERS-CoV 木瓜蛋白酶样蛋白酶具有去 ISGylating 和去泛素化活性。
Virology. 2014 Feb;450-451:64-70. doi: 10.1016/j.virol.2013.11.040. Epub 2013 Dec 22.
7
The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds.严重急性呼吸综合征冠状病毒木瓜样蛋白酶:结构、功能及设计的抗病毒化合物对其的抑制作用
Antiviral Res. 2015 Mar;115:21-38. doi: 10.1016/j.antiviral.2014.12.015. Epub 2014 Dec 29.
8
SARS-CoV-2 papain-like protease inhibits ISGylation of the viral nucleocapsid protein to evade host anti-viral immunity.SARS-CoV-2 木瓜蛋白酶样蛋白酶抑制病毒核衣壳蛋白的 ISG 化,从而逃避宿主抗病毒免疫。
J Virol. 2024 Sep 17;98(9):e0085524. doi: 10.1128/jvi.00855-24. Epub 2024 Aug 9.
9
The SARS-CoV-2 papain-like protease suppresses type I interferon responses by deubiquitinating STING.严重急性呼吸综合征冠状病毒 2 型木瓜蛋白酶样蛋白酶通过去泛素化 STING 抑制 I 型干扰素反应。
Sci Signal. 2023 May 2;16(783):eadd0082. doi: 10.1126/scisignal.add0082.
10
Characterization of the Ubiquitin and ISG15 Deconjugase Activity of SARS-CoV-1 and SARS-CoV-2 Papain-Like Protease.严重急性呼吸综合征冠状病毒1型和2型木瓜蛋白酶样蛋白酶的泛素及ISG15去结合酶活性的表征
Methods Mol Biol. 2023;2591:171-188. doi: 10.1007/978-1-0716-2803-4_11.

引用本文的文献

1
The Dual Role of cGAS-STING Signaling in COVID-19: Implications for Therapy.cGAS-STING信号通路在新冠病毒疾病中的双重作用:对治疗的启示
Cells. 2025 Feb 28;14(5):362. doi: 10.3390/cells14050362.
2
9-aminominocycline potentiates the efficacy of EIDD-1931 and PF-332 by targeting the papain like protease enzyme of SARS-CoV-2.9-氨基米诺环素通过靶向新冠病毒的木瓜蛋白酶样蛋白酶增强EIDD-1931和PF-332的疗效。
Sci Rep. 2025 Feb 15;15(1):5671. doi: 10.1038/s41598-025-89717-3.
3
Zinc as a Possible Critical Element to Prevent Harmful Effects of COVID-19 on Testicular Function: a Narrative Review.锌作为预防新冠病毒对睾丸功能产生有害影响的潜在关键元素:一项叙述性综述
Reprod Sci. 2024 Dec;31(12):3673-3687. doi: 10.1007/s43032-024-01638-0. Epub 2024 Jul 10.
4
Predicting human and viral protein variants affecting COVID-19 susceptibility and repurposing therapeutics.预测影响 COVID-19 易感性和重新利用治疗方法的人类和病毒蛋白变异体。
Sci Rep. 2024 Jun 20;14(1):14208. doi: 10.1038/s41598-024-61541-1.
5
Budesonide/formoterol combination for reducing cough in COVID-19 patients-A case of inflated expectations!布地奈德/福莫特罗联合用药对降低新冠肺炎患者咳嗽症状的疗效——一个期望过高的案例!
Lung India. 2023 Sep-Oct;40(5):483. doi: 10.4103/lungindia.lungindia_169_23.
6
Preferability of Molnupiravir, an Anti-COVID-19 Drug, toward Purine Nucleosides: A Quantum Mechanical Study.抗新冠病毒药物莫努匹拉韦对嘌呤核苷的偏好性:一项量子力学研究
ACS Omega. 2023 Jul 18;8(30):27553-27565. doi: 10.1021/acsomega.3c03215. eCollection 2023 Aug 1.
7
Dual domain recognition determines SARS-CoV-2 PLpro selectivity for human ISG15 and K48-linked di-ubiquitin.双结构域识别决定了 SARS-CoV-2 PLpro 对人 ISG15 和 K48 连接的二泛素的选择性。
Nat Commun. 2023 Apr 25;14(1):2366. doi: 10.1038/s41467-023-38031-5.
8
Effectiveness of budesonide formoterol fixed-dose combination MDI in reducing cough symptoms in COVID-19 patients: A real-world evidence study.布地奈德福莫特罗固定剂量复方气雾剂在减轻新冠病毒感染患者咳嗽症状方面的有效性:一项真实世界证据研究。
Lung India. 2023 Mar-Apr;40(2):107-111. doi: 10.4103/lungindia.lungindia_268_22.
9
Pharmacotherapeutic Potential of Natural Products to Target the SARS-CoV-2 PLpro Using Molecular Screening and Simulation Approaches.天然产物在靶向 SARS-CoV-2 PLpro 方面的药物治疗潜力:基于分子筛选和模拟方法的研究。
Appl Biochem Biotechnol. 2023 Nov;195(11):6959-6978. doi: 10.1007/s12010-023-04466-1. Epub 2023 Mar 24.
10
Highlights on molecular targets in the management of COVID-19: Possible role of pharmacogenomics.新型冠状病毒肺炎治疗的分子靶点概述:药物基因组学的可能作用。
J Int Med Res. 2023 Jan;51(1):3000605231153764. doi: 10.1177/03000605231153764.

本文引用的文献

1
6-Thioguanine blocks SARS-CoV-2 replication by inhibition of PLpro.6-硫鸟嘌呤通过抑制木瓜蛋白酶样蛋白酶(PLpro)来阻断新型冠状病毒2(SARS-CoV-2)的复制。
iScience. 2021 Oct 22;24(10):103213. doi: 10.1016/j.isci.2021.103213. Epub 2021 Oct 2.
2
An update review of emerging small-molecule therapeutic options for COVID-19.新冠病毒小分子治疗药物的最新研究进展综述。
Biomed Pharmacother. 2021 May;137:111313. doi: 10.1016/j.biopha.2021.111313. Epub 2021 Feb 3.
3
The complex structure of GRL0617 and SARS-CoV-2 PLpro reveals a hot spot for antiviral drug discovery.GRL0617 与 SARS-CoV-2 PLpro 的复杂结构揭示了抗病毒药物发现的热点。
Nat Commun. 2021 Jan 20;12(1):488. doi: 10.1038/s41467-020-20718-8.
4
COVID-19 and related symptoms in patients under disulfiram for alcohol use disorder.正在接受双硫仑治疗酒精使用障碍的患者中的新冠病毒疾病及相关症状
Intern Emerg Med. 2021 Sep;16(6):1729-1731. doi: 10.1007/s11739-021-02633-y. Epub 2021 Jan 19.
5
Repurposing Known Drugs as Covalent and Non-covalent Inhibitors of the SARS-CoV-2 Papain-Like Protease.将已知药物重新用作新型冠状病毒木瓜样蛋白酶的共价和非共价抑制剂
Front Chem. 2020 Nov 16;8:594009. doi: 10.3389/fchem.2020.594009. eCollection 2020.
6
Molecular docking of potential SARS-CoV-2 papain-like protease inhibitors.潜在 SARS-CoV-2 木瓜蛋白酶样蛋白酶抑制剂的分子对接。
Biochem Biophys Res Commun. 2021 Jan 29;538:72-79. doi: 10.1016/j.bbrc.2020.11.083. Epub 2020 Nov 28.
7
SARS-CoV-2-specific virulence factors in COVID-19.COVID-19 中的 SARS-CoV-2 特异性毒力因子。
J Med Virol. 2021 Mar;93(3):1343-1350. doi: 10.1002/jmv.26615. Epub 2020 Nov 1.
8
SARS-CoV-2: the many pros of targeting PLpro.严重急性呼吸综合征冠状病毒2:靶向木瓜蛋白酶样蛋白酶的诸多益处
Signal Transduct Target Ther. 2020 Oct 6;5(1):223. doi: 10.1038/s41392-020-00335-z.
9
Potential COVID-19 papain-like protease PL inhibitors: repurposing FDA-approved drugs.潜在的新型冠状病毒木瓜样蛋白酶PL抑制剂:重新利用美国食品药品监督管理局批准的药物。
PeerJ. 2020 Sep 18;8:e9965. doi: 10.7717/peerj.9965. eCollection 2020.
10
Papain-Like Proteases as Coronaviral Drug Targets: Current Inhibitors, Opportunities, and Limitations.木瓜蛋白酶样蛋白酶作为冠状病毒药物靶点:当前的抑制剂、机遇与局限
Pharmaceuticals (Basel). 2020 Sep 28;13(10):277. doi: 10.3390/ph13100277.

严重急性呼吸综合征冠状病毒 2 型木瓜蛋白酶样蛋白酶与免疫系统的相互作用:COVID-19 治疗的潜在药物靶点。

Interactions between SARS coronavirus 2 papain-like protease and immune system: A potential drug target for the treatment of COVID-19.

机构信息

Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Department of Virology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

出版信息

Scand J Immunol. 2021 Oct;94(4):e13044. doi: 10.1111/sji.13044. Epub 2021 Aug 10.

DOI:10.1111/sji.13044
PMID:33872387
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8250271/
Abstract

Coronaviruses (CoVs) are a large family of respiratory viruses which can cause mild to moderate upper respiratory tract infections. Recently, new coronavirus named as Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been identified which is a major threat to public health. Innate immune responses play a vital role in a host's defence against viruses. Interestingly, CoVs have evolved elaborate strategies to evade the complex system of sensors and signalling molecules to suppress host immunity. SARS-CoV-2 papain-like protease (PLpro), as an important coronavirus enzyme, regulates viral spread and innate immune responses. SCoV-2 PLpro is multifunctional enzyme with deubiquitinating (DUB) and deISGylating activity. The PLpro can interact with key regulators in signalling pathways such as STING, NF-κB, cytokine production, MAPK and TGF-β and hijack those to block the immune responses. Therefore, the PLpro can be as an important target for the treatment of COVID-19. Until now, several drugs or compounds have been identified that can inhibit PLpro activity. Here we discuss about the dysregulation effects of PLpro on immune system and drugs that have potential inhibitors for SCoV-2 PLpro.

摘要

冠状病毒(CoV)是一类能够引起轻度至中度呼吸道感染的大型呼吸道病毒家族。最近,一种名为严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)的新型冠状病毒已被确定,它对公众健康构成了重大威胁。先天免疫反应在宿主抵抗病毒的防御中起着至关重要的作用。有趣的是,CoV 已经进化出了精细的策略来逃避复杂的传感器和信号分子系统,以抑制宿主的免疫反应。SARS-CoV-2 木瓜蛋白酶样蛋白酶(PLpro)作为一种重要的冠状病毒酶,调节病毒的传播和先天免疫反应。SCoV-2 PLpro 是一种多功能酶,具有去泛素化(DUB)和去 ISG 基化活性。PLpro 可以与信号通路中的关键调节剂相互作用,如 STING、NF-κB、细胞因子产生、MAPK 和 TGF-β,并劫持这些调节剂来阻断免疫反应。因此,PLpro 可以作为治疗 COVID-19 的重要靶点。到目前为止,已经确定了几种可以抑制 PLpro 活性的药物或化合物。在这里,我们讨论了 PLpro 对免疫系统的失调作用,以及具有 SCoV-2 PLpro 潜在抑制剂的药物。